Comparison · NCT01667081-e8835b65
GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced a Drug-Related Adverse Event (AE) During the Long-Term Follow-Up
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced a Drug-Related Adverse Event (AE) During the Long-Term Follow-Up. Trial comparisons, record NCT01667081-e8835b65. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01667081-e8835b65
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.000524 | 0.0000925 | 0.00296 | wilson | |
| Risk in group 2 | 0.0019 | 0.000336 | 0.0107 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00138 | -0.0102 | 0.00152 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.276 | 0.0173 | 4.4 | log | |
| Odds ratio, group 1 over group 2 | 0.275 | 0.0172 | 4.41 | log | |
| Number needed to treat, for one fewer participant with the outcome on GZR 100 mg + EBR 50 mg +/- RBV than on Other GZR Regimen | 726 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GZR 100 mg + EBR 50 mg +/- RBV | Participants previously received GZR 100mg +EBR 50mg with or without RBV in a prior study. | 1 | 1,909 | OG000 |
| Group 2 | Other GZR Regimen | Participants previously received at least one dose of GZR in a prior study | 1 | 526 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Experienced a Drug-Related Adverse Event (AE) During the Long-Term Follow-Up
- Description
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The study investigator determined whether the adverse event was drug-related.
- Time frame
- Up to ~ 60 months after enrollment in this study
- Population
All participants treated with GZR in a prior study. Three participants were excluded from analysis; two participants enrolled in error failed to receive at least one dose of GZR in a prior study (each received a comparator regimen in a prior base study) and one participant had insufficient long-term follow-up data (participant withdrew consent on Day 27).
Source ClinicalTrials.gov
Trial
- Title
- Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
- NCT number
- NCT01667081
- Phases
- Conditions
- Hepatitis C
- Interventions
- Grazoprevir
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2022-06-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01667081?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01667081-e8835b65